Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development-Reference-Cited by-同舟云学术

Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development

Published:2013-10-24 Issue:11 Volume:10 Page:4055-4062
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Smelick Gillian S.¹,Heffron Timothy P.²,Chu Laura³,Dean Brian⁴,West David A.¹,DuVall Scott L.⁵,Lum Bert L.¹,Budha Nageshwar¹,Holden Scott N.⁶,Benet Leslie Z.⁷,Frymoyer Adam⁸,Dresser Mark J.¹,Ware Joseph A.¹

Affiliation:

1. Clinical Pharmacology, Genentech Research and Early Development, 1 DNA Way, South San Francisco, California 94080, United States

2. Genentech Medicinal Chemistry, 1 DNA Way, South San Francisco, California 94080, United States

3. Genentech Epidemiology, 1 DNA Way, South San Francisco, California 94080, United States

4. Drug Metabolism and Pharmacokinetics, Genentech Research and Early Development, 1 DNA Way, South San Francisco, California 94080, United States

5. VA Salt Lake City Health Care System, Clinical Epidemiology, Internal Medicine, University of Utah, Salt Lake City, Utah 84148, United States

6. Early Clinical Development, Genentech Research and Early Development, 1 DNA Way, South San Francisco, California 94080, United States

7. Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California 94143-0912, United States

8. Department of Pediatrics, Stanford University, Palo Alto, California 94304, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/mp400403s

Reference39 articles.

1. The Prevalence of and the Clinical and Demographic Characteristics Associated With High-Intensity Proton Pump Inhibitor Use

2. Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents

3. Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects

4. The US Food and Drug Administration.Erlotinib (Tarceva) Prescribing Information. 2010.

5. The US Food and Drug Administration.Dasatinib (Sprycel) Prescribing Information. 2011.

Cited by 150 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of proton pump inhibitors on pathologic response rates following fluoropyrimidine‐based neoadjuvant chemotherapy in pancreatic cancer patients;Journal of Surgical Oncology;2024-09-11

2. The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions;European Journal of Drug Metabolism and Pharmacokinetics;2024-08-06

3. Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients;The Prostate;2024-07-10

4. Playing Hide-and-Seek with Tyrosine Kinase Inhibitors: Can We Overcome Administration Challenges?;The AAPS Journal;2024-06-11

5. Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis;Frontiers in Pharmacology;2024-05-06